BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29517858)

  • 1. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
    Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
    Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P; Zhang J; Shang C; Zhang L
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
    Zhao F; Xu M; Lei H; Zhou Z; Wang L; Li P; Zhao J; Hu P
    PLoS One; 2015; 10(2):e0117333. PubMed ID: 25706305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
    Inamura K; Takeuchi K; Togashi Y; Hatano S; Ninomiya H; Motoi N; Mun MY; Sakao Y; Okumura S; Nakagawa K; Soda M; Choi YL; Mano H; Ishikawa Y
    Mod Pathol; 2009 Apr; 22(4):508-15. PubMed ID: 19234440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
    Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
    Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
    Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
    Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
    Fukui T; Yatabe Y; Kobayashi Y; Tomizawa K; Ito S; Hatooka S; Matsuo K; Mitsudomi T
    Lung Cancer; 2012 Aug; 77(2):319-25. PubMed ID: 22483782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
    Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
    Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.
    Wang H; Zhang W; Wang K; Li X
    Medicine (Baltimore); 2018 Jun; 97(26):e11116. PubMed ID: 29952952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
    Murakami S; Yokose T; Saito H; Sakuma Y; Matsukuma S; Hasegawa C; Kondo T; Oshita F; Ito H; Tsuboi M; Nakayama H; Kameda Y; Noda K; Yamada K
    Lung Cancer; 2010 Sep; 69(3):361-4. PubMed ID: 20659620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of ALK fusion in lung cancer using fluorescence in situ hybridization.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Kikuchi R; Date H
    Asian Cardiovasc Thorac Ann; 2012 Aug; 20(4):426-31. PubMed ID: 22879549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.